Antihypertensive Properties of the Novel Calcium Antagonist Mibefradil (Ro 40-5967): A New Generation of Calcium Antagonists?

Hypertension

Volumn 27, Issue 3 I, 1996, Pages 426-432

  Bernink, Peter J L M ^a   Prager, Gerold ^b   Schelling, Arie ^b   Kobrin, Isaac ^b  

^a MARTINI HOSPITAL   (Netherlands)

^b NONE

Author keywords

Antihypertensive agents; Calcium antagonists; Essential; Heart rate; Hypertension; Mibefradil

Indexed keywords

CALCIUM ANTAGONIST; MIBEFRADIL; PLACEBO;

ADULT; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FEMALE; FLUSHING; HEADACHE; HEART RATE; HUMAN; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADOLESCENT; ADULT; BENZIMIDAZOLES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIBEFRADIL; MIDDLE AGED; TETRAHYDRONAPHTHALENES;

EID: 0029885746     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.27.3.426     Document Type: Article

References (26)

1. Kaplan NM. Calcium entry blockers in the treatment of hypertension. JAMA. 1989;262:817-823.
2. Oparil S, Calhoun DA. The calcium antagonist in the 1990s: an overview. Am J Hypertens. 1991;4:396S-405S.
3. Triggle DJ. Sites, mechanism of action and differentiation of calcium channel antagonists. Am J Hypertens. 1991;4:422S-429S.
4. Frohlich ED. Calcium antagonists: their physiological differences. Am J Hypertens. 1991;4:430S-434S.
5. Wood A. Calcium antagonists: pharmacologic differences and similarities. Circulation. 1989;80(suppl IV):IV-84-IV-88.
6. Braunwald E. Mechanism of action of calcium channel blocking agents. N Engl J Med. 1982;307:1618-1627.
7. 2+ channel blocker with potent vasodilator but weak inotropic action. J Cardiovasc Pharmacol. 1989;13:754-759.
8. 2+ channels by Ro 40-5967. Circ Res. 1994;75:144-148.
9. 2+ channel in cardiac tissue. Eur J Phannacol. 1995; 290:155-158.
10. Clozel JP, Osterrieder W, Kleinbloesem CH, Welker HA, Schlappi B, Tudor R, Hefti F, Schmitt R, Eggers H. Ro 40-5967: a new nondihydropyridine calcium antagonist. Cardiovasc Drug Rev. 1991; 9:4-17.
11. Schmitt R, Kleinbloesem CH, Belz GO. Schroeter V, Feifel U, Pozenel H, Kirch W, Halabi A, Woittiez AJ, Welker HA, van Brummelen P. Hemodynamic and humoral effect of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Phannacol Ther. 1992;52:314-323.
12. Portegies MCM, Schmitt R, Kraaij CJ, Braat SHJG, Gassner A, Hagemeijer F, Pozenel H, Prager G, Viersma JW, van der Wall EE, Kleinbloesem CH, Lie KI. Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris. J Cardiovasc Phannacol. 1991;18:746-751.
13. Chapelle F, Stoleru L, Hayashida W, Pouleur H, Hess O, Benedict CR, Rousseau MF. Ro 40-5967, a new calcium antagonist profile: bradycardia without myocardial depression? Circulation. 1994; 4:1928. Abstract.
14. Clozel JP, Banken L, Osterrieder W. Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil. J Cardiovasc Pharmacol. 1989;14:713-721.
15. 3H] desmethoxy-verapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther. 1990;4:731-736.
16. Welker HA, Eggers H, Kleinbloesem CH, Erb K, Breithaupt K, Butzer R, Belz GG. Ro 40-5967: pharmacokinetics of a new calcium antagonist. Eur J Clin Pharmacol. 1989;36(suppl):A304.
17. Guth BD. Reduction of exercise-induced regional contractile dysfunction in dogs using a novel calcium channel Mocker (Ro 40-5967). Cardiovasc Drugs Ther. 1992;6:167-171.
18. Veniant M, Clozel JP, Wolfgang R. Ro 40-5967 in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction. J Cardiovasc Pharmacol. 1991;17: 272-284.
19. Kiowski W, Bühler FR, Fadayomi MO, Erne P, Müller FB, Hulthen UL, Bolli P. Age, race, blood pressure and renin: predictors for antihypertensive treatment with calcium antagonists. Am J Cardiol. 1985;56:81H-85H.
20. Billman GE, Halliwil JR, Avendano CE. Effect of calcium channel antagonists on the cardiac vagal tone response to submaximal exercise. Drag Development Research. 1992;27:89-106.
21. Viskoper JR, Peters J, Laszt A, Yosephy C. Interaction of atenolol + Ro 40-5967, a novel class calcium antagonist, on AV conduction, heart rate and blood pressure. In: Abstracts of the 15th Scientific Meeting of the International Society of Hypertension; April 19-20, 1994; Melbourne, Australia. Abstract 155.
22. Gillum RF, Makuc DM. Feldman JJ. Pulse rate, coronary heart disease and death: the NHANES I Epidemiologic Follow-up Study. Am Heart J. 1991;121:172-177.
23. Thaulow E, Erikssen JE. How important is heart rate? J Hypertens, 1991;9(suppl 17):527-530.
24. Dyer AR, Persky V, Stamler J, Paul O, Shakelle RB, Berkson DM, Lepper M, Schoenberger JA, Lindberg HA. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol. 1980;112: 736-749.
25. Perski A, Olsson G, Landou C, Faire U, Tleorell T, Hamsten A. Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J. 1992;123:609-619.
26. Kannel WB, Kannel C, Paffenberger RS, Cupples LA. Heart rate and cardiovascular mortality: the Framingham study. Am Heart J. 1987;113:1489-1494.